Caprolactam Chemicals Limited has formally announced its Board of Directors meeting scheduled for February 13, 2026, to review the company's quarterly financial performance and consider dividend distribution to shareholders.

Board Meeting Details

The company has communicated to BSE Limited regarding the upcoming board meeting, which will be held on Friday, February 13, 2026, at 4:00 PM. The meeting agenda includes two primary items for consideration and approval.

Financial Results and Dividend Consideration

The board will deliberate on the unaudited financial results for the quarter ended December 31, 2025, marking the third quarter of the financial year 2026. Additionally, the directors will evaluate and potentially recommend dividend payment on equity shares, subject to the company's financial performance and available reserves.

Trading Window Restrictions

In compliance with regulatory requirements, Caprolactam Chemicals Limited has implemented trading window restrictions for designated persons and their relatives. The company has established these measures pursuant to its code to regulate, monitor and report trading by insiders.

Regulatory Compliance

The announcement has been made in accordance with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Siddharth Shankarlal Bhanushali, Director of the company, bearing DIN: 01721586, and dated January 27, 2026.

The company has requested BSE Limited to inform its members about the scheduled board meeting and associated trading restrictions, ensuring transparency and regulatory compliance in its corporate governance practices.

Caprolactam Chemicals Limited , a company listed on the BSE, has reported a significant change in its shareholding pattern following a recent acquisition by one of its promoters. Shital S. Bhanushali, a key stakeholder in the company, has substantially increased their ownership through an open market purchase.

Acquisition Details

Shital S. Bhanushali acquired an additional 5,420 shares of Caprolactam Chemicals Limited through an open market transaction. This acquisition has resulted in a notable increase in their total shareholding, as detailed below:

The transaction was completed on 28.11.2025 and disclosed in accordance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations.

Impact on Promoter Holding

This acquisition reinforces the promoter's commitment to the company and significantly increases their stake. The exact shareholding percentages of other promoters are not provided in the available information.

Company Overview

Caprolactam Chemicals Limited is a chemical company listed on the BSE. The recent acquisition by Shital S. Bhanushali demonstrates continued interest and investment from the promoter group in the company.

This acquisition and the resulting change in shareholding pattern have been duly reported to the stock exchange, maintaining transparency in line with regulatory requirements.